Frontiers in Pharmacology-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=1247445, encodeId=b238124e445bc, content=偏重的研究方向：民族药理学;中药复方 经验分享：投稿第三天就收到上传原始数据的邮箱了。实验结果的原始数据好好，第一次遇到连把数据库下载的原始数据也要提供😄, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=224, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Tue Sep 06 12:10:42 CST 2022, time=2022-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224914, encodeId=fdc312249140c, content=有没有人知道，已经有了 handing editor 还仍然一直处于Editor Assigntment 阶段，一直不进入独立审稿是什么原因, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e3e6569517, createdName=ms4000001809359020, createdTime=Tue Jun 07 09:35:51 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211736, encodeId=d2e61211e3684, content=审稿速度:1.0 经验分享：问一下各位战友！independent Review阶段总共3位Reviewer，2位Reviewer给出了一些意见直接endorsed，1个Reviewer rejected，之后直接跳过了Interactive Review直接进入Review Finalized，互动论坛关闭，显示Review is ongoing，这个阶段我要重新提交修改过的手稿吗？还是先等待流程？求助各位战友！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07c65460274, createdName=ms1000000668586258, createdTime=Sat Apr 16 20:44:00 CST 2022, time=2022-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052871, encodeId=5d7f10528e123, content=偏重的研究方向：肿瘤 经验分享：The Associate Editor ✘✘is evaluating any revisions made to the manuscript to take a final decision。2个审稿人都endorsed了，这个一般要等多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=162, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35cb90736, createdName=kimbryant, createdTime=Sat Sep 18 19:22:37 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2181567, encodeId=3ab4218156e26, content=请问投稿后收到拒稿理由是：Ethical issues or Integrity concerns, or other breach of policy were identified in this manuscript that prevent further review or publication.是为什么呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=705f8475329, createdName=ms3000001867061317, createdTime=Sun Jan 14 16:14:08 CST 2024, time=2024-01-14, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1219504, encodeId=dfa8121950457, content=偏重的研究方向：中药 经验分享：投稿三周了还是Initial Validation正常嘛？？？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ff275558303, createdName=ms6000000643924855, createdTime=Sat May 14 02:51:05 CST 2022, time=2022-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068061, encodeId=3e2810680610e, content=请教大家：Independent Review阶段审稿人1和2分别提了3个和8个问题，编辑给了大修，审稿人3同意发表；回答了审稿人1和2的问题，提交修改稿后，开始显示的是Reviewer 1 and 2 are due to discuss in the interactive forum. 2天后，状态变为：We are awaiting a response from Reviewer 2 in the interactive forum.目前editor, reviewer 1 and 2状态都是active. 意思是审稿人1已经对修改稿做出了评价吗？状态还是active意味着审稿人1还是不支持发表？这个杂志的审稿过程与其他杂志相差太大了。有知道的战友，请告诉我哈，非常感谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=6aec55499, createdName=xnjbao, createdTime=Mon Nov 08 10:15:51 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208745, encodeId=97641208e45f2, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：药理学 经验分享：The Associate Editor is evaluating any revisions made to the manuscript to take a final decision. 在编辑这里停留了两周了，请问这是什么情况？ 之前两个审稿人，一个直接给了endorsed，一个revision后给了endorsed；现在编辑再做final decision 请问各位大神有相似的经验吗？ 23 Mar 2022 Review of Review Editor 2 finalized. 17 Mar 2022 Corresponding Author posted new comments. 26 Feb 2022 Interactive review forum activated automatically. 03 Feb 2022 Review of Reviewer 1 is finalized. 17 Jan 2022 Corresponding Autho submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=470d5595758, createdName=ms6000001226186802, createdTime=Tue Apr 05 12:00:40 CST 2022, time=2022-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051477, encodeId=e4b210514e733, content=请问官网publish之后，什么时候能在wos上检索得到呢？现在只有官网上才能查到, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210915/71f2be7dffda4b2fa4182e3c51618e51/c3ba98af130a45c79094f8381f667b4e.jpg, createdBy=bcc15439550, createdName=夏小正plus, createdTime=Wed Sep 15 13:17:45 CST 2021, time=2021-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972762, encodeId=c5129e2762bd, content=请问一下 substantial revision 接收概率大么？是小修的意思吗谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epS9bXfsQ9F45LRdNKKXSR3SceNj6EksI6D68yHJw3icDBH7OdtHgMsJZibhtxdrxsicRhanL2RGJv3Q/132, createdBy=968c2354707, createdName=陈述, createdTime=Fri Jun 11 09:07:16 CST 2021, time=2021-06-11, status=1, ipAttribution=)]

2022-09-06 ms4000001680289394

偏重的研究方向：民族药理学;中药复方
经验分享：投稿第三天就收到上传原始数据的邮箱了。实验结果的原始数据好好，第一次遇到连把数据库下载的原始数据也要提供😄

224 12

展开12条回复

[GetPortalCommentsPageByObjectIdResponse(id=1247445, encodeId=b238124e445bc, content=偏重的研究方向：民族药理学;中药复方 经验分享：投稿第三天就收到上传原始数据的邮箱了。实验结果的原始数据好好，第一次遇到连把数据库下载的原始数据也要提供😄, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=224, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Tue Sep 06 12:10:42 CST 2022, time=2022-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224914, encodeId=fdc312249140c, content=有没有人知道，已经有了 handing editor 还仍然一直处于Editor Assigntment 阶段，一直不进入独立审稿是什么原因, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e3e6569517, createdName=ms4000001809359020, createdTime=Tue Jun 07 09:35:51 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211736, encodeId=d2e61211e3684, content=审稿速度:1.0 经验分享：问一下各位战友！independent Review阶段总共3位Reviewer，2位Reviewer给出了一些意见直接endorsed，1个Reviewer rejected，之后直接跳过了Interactive Review直接进入Review Finalized，互动论坛关闭，显示Review is ongoing，这个阶段我要重新提交修改过的手稿吗？还是先等待流程？求助各位战友！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07c65460274, createdName=ms1000000668586258, createdTime=Sat Apr 16 20:44:00 CST 2022, time=2022-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052871, encodeId=5d7f10528e123, content=偏重的研究方向：肿瘤 经验分享：The Associate Editor ✘✘is evaluating any revisions made to the manuscript to take a final decision。2个审稿人都endorsed了，这个一般要等多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=162, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35cb90736, createdName=kimbryant, createdTime=Sat Sep 18 19:22:37 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2181567, encodeId=3ab4218156e26, content=请问投稿后收到拒稿理由是：Ethical issues or Integrity concerns, or other breach of policy were identified in this manuscript that prevent further review or publication.是为什么呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=705f8475329, createdName=ms3000001867061317, createdTime=Sun Jan 14 16:14:08 CST 2024, time=2024-01-14, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1219504, encodeId=dfa8121950457, content=偏重的研究方向：中药 经验分享：投稿三周了还是Initial Validation正常嘛？？？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ff275558303, createdName=ms6000000643924855, createdTime=Sat May 14 02:51:05 CST 2022, time=2022-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068061, encodeId=3e2810680610e, content=请教大家：Independent Review阶段审稿人1和2分别提了3个和8个问题，编辑给了大修，审稿人3同意发表；回答了审稿人1和2的问题，提交修改稿后，开始显示的是Reviewer 1 and 2 are due to discuss in the interactive forum. 2天后，状态变为：We are awaiting a response from Reviewer 2 in the interactive forum.目前editor, reviewer 1 and 2状态都是active. 意思是审稿人1已经对修改稿做出了评价吗？状态还是active意味着审稿人1还是不支持发表？这个杂志的审稿过程与其他杂志相差太大了。有知道的战友，请告诉我哈，非常感谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=6aec55499, createdName=xnjbao, createdTime=Mon Nov 08 10:15:51 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208745, encodeId=97641208e45f2, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：药理学 经验分享：The Associate Editor is evaluating any revisions made to the manuscript to take a final decision. 在编辑这里停留了两周了，请问这是什么情况？ 之前两个审稿人，一个直接给了endorsed，一个revision后给了endorsed；现在编辑再做final decision 请问各位大神有相似的经验吗？ 23 Mar 2022 Review of Review Editor 2 finalized. 17 Mar 2022 Corresponding Author posted new comments. 26 Feb 2022 Interactive review forum activated automatically. 03 Feb 2022 Review of Reviewer 1 is finalized. 17 Jan 2022 Corresponding Autho submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=470d5595758, createdName=ms6000001226186802, createdTime=Tue Apr 05 12:00:40 CST 2022, time=2022-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051477, encodeId=e4b210514e733, content=请问官网publish之后，什么时候能在wos上检索得到呢？现在只有官网上才能查到, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210915/71f2be7dffda4b2fa4182e3c51618e51/c3ba98af130a45c79094f8381f667b4e.jpg, createdBy=bcc15439550, createdName=夏小正plus, createdTime=Wed Sep 15 13:17:45 CST 2021, time=2021-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972762, encodeId=c5129e2762bd, content=请问一下 substantial revision 接收概率大么？是小修的意思吗谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epS9bXfsQ9F45LRdNKKXSR3SceNj6EksI6D68yHJw3icDBH7OdtHgMsJZibhtxdrxsicRhanL2RGJv3Q/132, createdBy=968c2354707, createdName=陈述, createdTime=Fri Jun 11 09:07:16 CST 2021, time=2021-06-11, status=1, ipAttribution=)]

2022-06-07 ms4000001809359020

有没有人知道，已经有了 handing editor 还仍然一直处于Editor Assigntment 阶段，一直不进入独立审稿是什么原因

69 12

展开12条回复

[GetPortalCommentsPageByObjectIdResponse(id=1247445, encodeId=b238124e445bc, content=偏重的研究方向：民族药理学;中药复方 经验分享：投稿第三天就收到上传原始数据的邮箱了。实验结果的原始数据好好，第一次遇到连把数据库下载的原始数据也要提供😄, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=224, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Tue Sep 06 12:10:42 CST 2022, time=2022-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224914, encodeId=fdc312249140c, content=有没有人知道，已经有了 handing editor 还仍然一直处于Editor Assigntment 阶段，一直不进入独立审稿是什么原因, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e3e6569517, createdName=ms4000001809359020, createdTime=Tue Jun 07 09:35:51 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211736, encodeId=d2e61211e3684, content=审稿速度:1.0 经验分享：问一下各位战友！independent Review阶段总共3位Reviewer，2位Reviewer给出了一些意见直接endorsed，1个Reviewer rejected，之后直接跳过了Interactive Review直接进入Review Finalized，互动论坛关闭，显示Review is ongoing，这个阶段我要重新提交修改过的手稿吗？还是先等待流程？求助各位战友！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07c65460274, createdName=ms1000000668586258, createdTime=Sat Apr 16 20:44:00 CST 2022, time=2022-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052871, encodeId=5d7f10528e123, content=偏重的研究方向：肿瘤 经验分享：The Associate Editor ✘✘is evaluating any revisions made to the manuscript to take a final decision。2个审稿人都endorsed了，这个一般要等多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=162, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35cb90736, createdName=kimbryant, createdTime=Sat Sep 18 19:22:37 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2181567, encodeId=3ab4218156e26, content=请问投稿后收到拒稿理由是：Ethical issues or Integrity concerns, or other breach of policy were identified in this manuscript that prevent further review or publication.是为什么呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=705f8475329, createdName=ms3000001867061317, createdTime=Sun Jan 14 16:14:08 CST 2024, time=2024-01-14, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1219504, encodeId=dfa8121950457, content=偏重的研究方向：中药 经验分享：投稿三周了还是Initial Validation正常嘛？？？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ff275558303, createdName=ms6000000643924855, createdTime=Sat May 14 02:51:05 CST 2022, time=2022-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068061, encodeId=3e2810680610e, content=请教大家：Independent Review阶段审稿人1和2分别提了3个和8个问题，编辑给了大修，审稿人3同意发表；回答了审稿人1和2的问题，提交修改稿后，开始显示的是Reviewer 1 and 2 are due to discuss in the interactive forum. 2天后，状态变为：We are awaiting a response from Reviewer 2 in the interactive forum.目前editor, reviewer 1 and 2状态都是active. 意思是审稿人1已经对修改稿做出了评价吗？状态还是active意味着审稿人1还是不支持发表？这个杂志的审稿过程与其他杂志相差太大了。有知道的战友，请告诉我哈，非常感谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=6aec55499, createdName=xnjbao, createdTime=Mon Nov 08 10:15:51 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208745, encodeId=97641208e45f2, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：药理学 经验分享：The Associate Editor is evaluating any revisions made to the manuscript to take a final decision. 在编辑这里停留了两周了，请问这是什么情况？ 之前两个审稿人，一个直接给了endorsed，一个revision后给了endorsed；现在编辑再做final decision 请问各位大神有相似的经验吗？ 23 Mar 2022 Review of Review Editor 2 finalized. 17 Mar 2022 Corresponding Author posted new comments. 26 Feb 2022 Interactive review forum activated automatically. 03 Feb 2022 Review of Reviewer 1 is finalized. 17 Jan 2022 Corresponding Autho submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=470d5595758, createdName=ms6000001226186802, createdTime=Tue Apr 05 12:00:40 CST 2022, time=2022-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051477, encodeId=e4b210514e733, content=请问官网publish之后，什么时候能在wos上检索得到呢？现在只有官网上才能查到, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210915/71f2be7dffda4b2fa4182e3c51618e51/c3ba98af130a45c79094f8381f667b4e.jpg, createdBy=bcc15439550, createdName=夏小正plus, createdTime=Wed Sep 15 13:17:45 CST 2021, time=2021-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972762, encodeId=c5129e2762bd, content=请问一下 substantial revision 接收概率大么？是小修的意思吗谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epS9bXfsQ9F45LRdNKKXSR3SceNj6EksI6D68yHJw3icDBH7OdtHgMsJZibhtxdrxsicRhanL2RGJv3Q/132, createdBy=968c2354707, createdName=陈述, createdTime=Fri Jun 11 09:07:16 CST 2021, time=2021-06-11, status=1, ipAttribution=)]

2022-04-16 ms1000000668586258

审稿速度:1.0
经验分享：问一下各位战友！independent Review阶段总共3位Reviewer，2位Reviewer给出了一些意见直接endorsed，1个Reviewer rejected，之后直接跳过了Interactive Review直接进入Review Finalized，互动论坛关闭，显示Review is ongoing，这个阶段我要重新提交修改过的手稿吗？还是先等待流程？求助各位战友！

84 12

展开12条回复

[GetPortalCommentsPageByObjectIdResponse(id=1247445, encodeId=b238124e445bc, content=偏重的研究方向：民族药理学;中药复方 经验分享：投稿第三天就收到上传原始数据的邮箱了。实验结果的原始数据好好，第一次遇到连把数据库下载的原始数据也要提供😄, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=224, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Tue Sep 06 12:10:42 CST 2022, time=2022-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224914, encodeId=fdc312249140c, content=有没有人知道，已经有了 handing editor 还仍然一直处于Editor Assigntment 阶段，一直不进入独立审稿是什么原因, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e3e6569517, createdName=ms4000001809359020, createdTime=Tue Jun 07 09:35:51 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211736, encodeId=d2e61211e3684, content=审稿速度:1.0 经验分享：问一下各位战友！independent Review阶段总共3位Reviewer，2位Reviewer给出了一些意见直接endorsed，1个Reviewer rejected，之后直接跳过了Interactive Review直接进入Review Finalized，互动论坛关闭，显示Review is ongoing，这个阶段我要重新提交修改过的手稿吗？还是先等待流程？求助各位战友！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07c65460274, createdName=ms1000000668586258, createdTime=Sat Apr 16 20:44:00 CST 2022, time=2022-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052871, encodeId=5d7f10528e123, content=偏重的研究方向：肿瘤 经验分享：The Associate Editor ✘✘is evaluating any revisions made to the manuscript to take a final decision。2个审稿人都endorsed了，这个一般要等多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=162, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35cb90736, createdName=kimbryant, createdTime=Sat Sep 18 19:22:37 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2181567, encodeId=3ab4218156e26, content=请问投稿后收到拒稿理由是：Ethical issues or Integrity concerns, or other breach of policy were identified in this manuscript that prevent further review or publication.是为什么呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=705f8475329, createdName=ms3000001867061317, createdTime=Sun Jan 14 16:14:08 CST 2024, time=2024-01-14, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1219504, encodeId=dfa8121950457, content=偏重的研究方向：中药 经验分享：投稿三周了还是Initial Validation正常嘛？？？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ff275558303, createdName=ms6000000643924855, createdTime=Sat May 14 02:51:05 CST 2022, time=2022-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068061, encodeId=3e2810680610e, content=请教大家：Independent Review阶段审稿人1和2分别提了3个和8个问题，编辑给了大修，审稿人3同意发表；回答了审稿人1和2的问题，提交修改稿后，开始显示的是Reviewer 1 and 2 are due to discuss in the interactive forum. 2天后，状态变为：We are awaiting a response from Reviewer 2 in the interactive forum.目前editor, reviewer 1 and 2状态都是active. 意思是审稿人1已经对修改稿做出了评价吗？状态还是active意味着审稿人1还是不支持发表？这个杂志的审稿过程与其他杂志相差太大了。有知道的战友，请告诉我哈，非常感谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=6aec55499, createdName=xnjbao, createdTime=Mon Nov 08 10:15:51 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208745, encodeId=97641208e45f2, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：药理学 经验分享：The Associate Editor is evaluating any revisions made to the manuscript to take a final decision. 在编辑这里停留了两周了，请问这是什么情况？ 之前两个审稿人，一个直接给了endorsed，一个revision后给了endorsed；现在编辑再做final decision 请问各位大神有相似的经验吗？ 23 Mar 2022 Review of Review Editor 2 finalized. 17 Mar 2022 Corresponding Author posted new comments. 26 Feb 2022 Interactive review forum activated automatically. 03 Feb 2022 Review of Reviewer 1 is finalized. 17 Jan 2022 Corresponding Autho submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=470d5595758, createdName=ms6000001226186802, createdTime=Tue Apr 05 12:00:40 CST 2022, time=2022-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051477, encodeId=e4b210514e733, content=请问官网publish之后，什么时候能在wos上检索得到呢？现在只有官网上才能查到, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210915/71f2be7dffda4b2fa4182e3c51618e51/c3ba98af130a45c79094f8381f667b4e.jpg, createdBy=bcc15439550, createdName=夏小正plus, createdTime=Wed Sep 15 13:17:45 CST 2021, time=2021-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972762, encodeId=c5129e2762bd, content=请问一下 substantial revision 接收概率大么？是小修的意思吗谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epS9bXfsQ9F45LRdNKKXSR3SceNj6EksI6D68yHJw3icDBH7OdtHgMsJZibhtxdrxsicRhanL2RGJv3Q/132, createdBy=968c2354707, createdName=陈述, createdTime=Fri Jun 11 09:07:16 CST 2021, time=2021-06-11, status=1, ipAttribution=)]

2021-09-18 kimbryant

偏重的研究方向：肿瘤
经验分享：The Associate Editor ✘✘is evaluating any revisions made to the manuscript to take a final decision。2个审稿人都endorsed了，这个一般要等多久啊

162 11

展开11条回复

[GetPortalCommentsPageByObjectIdResponse(id=1247445, encodeId=b238124e445bc, content=偏重的研究方向：民族药理学;中药复方 经验分享：投稿第三天就收到上传原始数据的邮箱了。实验结果的原始数据好好，第一次遇到连把数据库下载的原始数据也要提供😄, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=224, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Tue Sep 06 12:10:42 CST 2022, time=2022-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224914, encodeId=fdc312249140c, content=有没有人知道，已经有了 handing editor 还仍然一直处于Editor Assigntment 阶段，一直不进入独立审稿是什么原因, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e3e6569517, createdName=ms4000001809359020, createdTime=Tue Jun 07 09:35:51 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211736, encodeId=d2e61211e3684, content=审稿速度:1.0 经验分享：问一下各位战友！independent Review阶段总共3位Reviewer，2位Reviewer给出了一些意见直接endorsed，1个Reviewer rejected，之后直接跳过了Interactive Review直接进入Review Finalized，互动论坛关闭，显示Review is ongoing，这个阶段我要重新提交修改过的手稿吗？还是先等待流程？求助各位战友！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07c65460274, createdName=ms1000000668586258, createdTime=Sat Apr 16 20:44:00 CST 2022, time=2022-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052871, encodeId=5d7f10528e123, content=偏重的研究方向：肿瘤 经验分享：The Associate Editor ✘✘is evaluating any revisions made to the manuscript to take a final decision。2个审稿人都endorsed了，这个一般要等多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=162, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35cb90736, createdName=kimbryant, createdTime=Sat Sep 18 19:22:37 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2181567, encodeId=3ab4218156e26, content=请问投稿后收到拒稿理由是：Ethical issues or Integrity concerns, or other breach of policy were identified in this manuscript that prevent further review or publication.是为什么呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=705f8475329, createdName=ms3000001867061317, createdTime=Sun Jan 14 16:14:08 CST 2024, time=2024-01-14, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1219504, encodeId=dfa8121950457, content=偏重的研究方向：中药 经验分享：投稿三周了还是Initial Validation正常嘛？？？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ff275558303, createdName=ms6000000643924855, createdTime=Sat May 14 02:51:05 CST 2022, time=2022-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068061, encodeId=3e2810680610e, content=请教大家：Independent Review阶段审稿人1和2分别提了3个和8个问题，编辑给了大修，审稿人3同意发表；回答了审稿人1和2的问题，提交修改稿后，开始显示的是Reviewer 1 and 2 are due to discuss in the interactive forum. 2天后，状态变为：We are awaiting a response from Reviewer 2 in the interactive forum.目前editor, reviewer 1 and 2状态都是active. 意思是审稿人1已经对修改稿做出了评价吗？状态还是active意味着审稿人1还是不支持发表？这个杂志的审稿过程与其他杂志相差太大了。有知道的战友，请告诉我哈，非常感谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=6aec55499, createdName=xnjbao, createdTime=Mon Nov 08 10:15:51 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208745, encodeId=97641208e45f2, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：药理学 经验分享：The Associate Editor is evaluating any revisions made to the manuscript to take a final decision. 在编辑这里停留了两周了，请问这是什么情况？ 之前两个审稿人，一个直接给了endorsed，一个revision后给了endorsed；现在编辑再做final decision 请问各位大神有相似的经验吗？ 23 Mar 2022 Review of Review Editor 2 finalized. 17 Mar 2022 Corresponding Author posted new comments. 26 Feb 2022 Interactive review forum activated automatically. 03 Feb 2022 Review of Reviewer 1 is finalized. 17 Jan 2022 Corresponding Autho submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=470d5595758, createdName=ms6000001226186802, createdTime=Tue Apr 05 12:00:40 CST 2022, time=2022-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051477, encodeId=e4b210514e733, content=请问官网publish之后，什么时候能在wos上检索得到呢？现在只有官网上才能查到, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210915/71f2be7dffda4b2fa4182e3c51618e51/c3ba98af130a45c79094f8381f667b4e.jpg, createdBy=bcc15439550, createdName=夏小正plus, createdTime=Wed Sep 15 13:17:45 CST 2021, time=2021-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972762, encodeId=c5129e2762bd, content=请问一下 substantial revision 接收概率大么？是小修的意思吗谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epS9bXfsQ9F45LRdNKKXSR3SceNj6EksI6D68yHJw3icDBH7OdtHgMsJZibhtxdrxsicRhanL2RGJv3Q/132, createdBy=968c2354707, createdName=陈述, createdTime=Fri Jun 11 09:07:16 CST 2021, time=2021-06-11, status=1, ipAttribution=)]

2024-01-14 ms3000001867061317 来自山东省

请问投稿后收到拒稿理由是：Ethical issues or Integrity concerns, or other breach of policy were identified in this manuscript that prevent further review or publication.是为什么呀

76 10

展开10条回复

[GetPortalCommentsPageByObjectIdResponse(id=1247445, encodeId=b238124e445bc, content=偏重的研究方向：民族药理学;中药复方 经验分享：投稿第三天就收到上传原始数据的邮箱了。实验结果的原始数据好好，第一次遇到连把数据库下载的原始数据也要提供😄, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=224, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Tue Sep 06 12:10:42 CST 2022, time=2022-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224914, encodeId=fdc312249140c, content=有没有人知道，已经有了 handing editor 还仍然一直处于Editor Assigntment 阶段，一直不进入独立审稿是什么原因, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e3e6569517, createdName=ms4000001809359020, createdTime=Tue Jun 07 09:35:51 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211736, encodeId=d2e61211e3684, content=审稿速度:1.0 经验分享：问一下各位战友！independent Review阶段总共3位Reviewer，2位Reviewer给出了一些意见直接endorsed，1个Reviewer rejected，之后直接跳过了Interactive Review直接进入Review Finalized，互动论坛关闭，显示Review is ongoing，这个阶段我要重新提交修改过的手稿吗？还是先等待流程？求助各位战友！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07c65460274, createdName=ms1000000668586258, createdTime=Sat Apr 16 20:44:00 CST 2022, time=2022-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052871, encodeId=5d7f10528e123, content=偏重的研究方向：肿瘤 经验分享：The Associate Editor ✘✘is evaluating any revisions made to the manuscript to take a final decision。2个审稿人都endorsed了，这个一般要等多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=162, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35cb90736, createdName=kimbryant, createdTime=Sat Sep 18 19:22:37 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2181567, encodeId=3ab4218156e26, content=请问投稿后收到拒稿理由是：Ethical issues or Integrity concerns, or other breach of policy were identified in this manuscript that prevent further review or publication.是为什么呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=705f8475329, createdName=ms3000001867061317, createdTime=Sun Jan 14 16:14:08 CST 2024, time=2024-01-14, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1219504, encodeId=dfa8121950457, content=偏重的研究方向：中药 经验分享：投稿三周了还是Initial Validation正常嘛？？？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ff275558303, createdName=ms6000000643924855, createdTime=Sat May 14 02:51:05 CST 2022, time=2022-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068061, encodeId=3e2810680610e, content=请教大家：Independent Review阶段审稿人1和2分别提了3个和8个问题，编辑给了大修，审稿人3同意发表；回答了审稿人1和2的问题，提交修改稿后，开始显示的是Reviewer 1 and 2 are due to discuss in the interactive forum. 2天后，状态变为：We are awaiting a response from Reviewer 2 in the interactive forum.目前editor, reviewer 1 and 2状态都是active. 意思是审稿人1已经对修改稿做出了评价吗？状态还是active意味着审稿人1还是不支持发表？这个杂志的审稿过程与其他杂志相差太大了。有知道的战友，请告诉我哈，非常感谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=6aec55499, createdName=xnjbao, createdTime=Mon Nov 08 10:15:51 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208745, encodeId=97641208e45f2, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：药理学 经验分享：The Associate Editor is evaluating any revisions made to the manuscript to take a final decision. 在编辑这里停留了两周了，请问这是什么情况？ 之前两个审稿人，一个直接给了endorsed，一个revision后给了endorsed；现在编辑再做final decision 请问各位大神有相似的经验吗？ 23 Mar 2022 Review of Review Editor 2 finalized. 17 Mar 2022 Corresponding Author posted new comments. 26 Feb 2022 Interactive review forum activated automatically. 03 Feb 2022 Review of Reviewer 1 is finalized. 17 Jan 2022 Corresponding Autho submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=470d5595758, createdName=ms6000001226186802, createdTime=Tue Apr 05 12:00:40 CST 2022, time=2022-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051477, encodeId=e4b210514e733, content=请问官网publish之后，什么时候能在wos上检索得到呢？现在只有官网上才能查到, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210915/71f2be7dffda4b2fa4182e3c51618e51/c3ba98af130a45c79094f8381f667b4e.jpg, createdBy=bcc15439550, createdName=夏小正plus, createdTime=Wed Sep 15 13:17:45 CST 2021, time=2021-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972762, encodeId=c5129e2762bd, content=请问一下 substantial revision 接收概率大么？是小修的意思吗谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epS9bXfsQ9F45LRdNKKXSR3SceNj6EksI6D68yHJw3icDBH7OdtHgMsJZibhtxdrxsicRhanL2RGJv3Q/132, createdBy=968c2354707, createdName=陈述, createdTime=Fri Jun 11 09:07:16 CST 2021, time=2021-06-11, status=1, ipAttribution=)]

2022-05-14 ms6000000643924855

偏重的研究方向：中药
经验分享：投稿三周了还是Initial Validation正常嘛？？？

48 10

展开10条回复

[GetPortalCommentsPageByObjectIdResponse(id=1247445, encodeId=b238124e445bc, content=偏重的研究方向：民族药理学;中药复方 经验分享：投稿第三天就收到上传原始数据的邮箱了。实验结果的原始数据好好，第一次遇到连把数据库下载的原始数据也要提供😄, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=224, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Tue Sep 06 12:10:42 CST 2022, time=2022-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224914, encodeId=fdc312249140c, content=有没有人知道，已经有了 handing editor 还仍然一直处于Editor Assigntment 阶段，一直不进入独立审稿是什么原因, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e3e6569517, createdName=ms4000001809359020, createdTime=Tue Jun 07 09:35:51 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211736, encodeId=d2e61211e3684, content=审稿速度:1.0 经验分享：问一下各位战友！independent Review阶段总共3位Reviewer，2位Reviewer给出了一些意见直接endorsed，1个Reviewer rejected，之后直接跳过了Interactive Review直接进入Review Finalized，互动论坛关闭，显示Review is ongoing，这个阶段我要重新提交修改过的手稿吗？还是先等待流程？求助各位战友！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07c65460274, createdName=ms1000000668586258, createdTime=Sat Apr 16 20:44:00 CST 2022, time=2022-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052871, encodeId=5d7f10528e123, content=偏重的研究方向：肿瘤 经验分享：The Associate Editor ✘✘is evaluating any revisions made to the manuscript to take a final decision。2个审稿人都endorsed了，这个一般要等多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=162, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35cb90736, createdName=kimbryant, createdTime=Sat Sep 18 19:22:37 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2181567, encodeId=3ab4218156e26, content=请问投稿后收到拒稿理由是：Ethical issues or Integrity concerns, or other breach of policy were identified in this manuscript that prevent further review or publication.是为什么呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=705f8475329, createdName=ms3000001867061317, createdTime=Sun Jan 14 16:14:08 CST 2024, time=2024-01-14, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1219504, encodeId=dfa8121950457, content=偏重的研究方向：中药 经验分享：投稿三周了还是Initial Validation正常嘛？？？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ff275558303, createdName=ms6000000643924855, createdTime=Sat May 14 02:51:05 CST 2022, time=2022-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068061, encodeId=3e2810680610e, content=请教大家：Independent Review阶段审稿人1和2分别提了3个和8个问题，编辑给了大修，审稿人3同意发表；回答了审稿人1和2的问题，提交修改稿后，开始显示的是Reviewer 1 and 2 are due to discuss in the interactive forum. 2天后，状态变为：We are awaiting a response from Reviewer 2 in the interactive forum.目前editor, reviewer 1 and 2状态都是active. 意思是审稿人1已经对修改稿做出了评价吗？状态还是active意味着审稿人1还是不支持发表？这个杂志的审稿过程与其他杂志相差太大了。有知道的战友，请告诉我哈，非常感谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=6aec55499, createdName=xnjbao, createdTime=Mon Nov 08 10:15:51 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208745, encodeId=97641208e45f2, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：药理学 经验分享：The Associate Editor is evaluating any revisions made to the manuscript to take a final decision. 在编辑这里停留了两周了，请问这是什么情况？ 之前两个审稿人，一个直接给了endorsed，一个revision后给了endorsed；现在编辑再做final decision 请问各位大神有相似的经验吗？ 23 Mar 2022 Review of Review Editor 2 finalized. 17 Mar 2022 Corresponding Author posted new comments. 26 Feb 2022 Interactive review forum activated automatically. 03 Feb 2022 Review of Reviewer 1 is finalized. 17 Jan 2022 Corresponding Autho submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=470d5595758, createdName=ms6000001226186802, createdTime=Tue Apr 05 12:00:40 CST 2022, time=2022-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051477, encodeId=e4b210514e733, content=请问官网publish之后，什么时候能在wos上检索得到呢？现在只有官网上才能查到, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210915/71f2be7dffda4b2fa4182e3c51618e51/c3ba98af130a45c79094f8381f667b4e.jpg, createdBy=bcc15439550, createdName=夏小正plus, createdTime=Wed Sep 15 13:17:45 CST 2021, time=2021-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972762, encodeId=c5129e2762bd, content=请问一下 substantial revision 接收概率大么？是小修的意思吗谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epS9bXfsQ9F45LRdNKKXSR3SceNj6EksI6D68yHJw3icDBH7OdtHgMsJZibhtxdrxsicRhanL2RGJv3Q/132, createdBy=968c2354707, createdName=陈述, createdTime=Fri Jun 11 09:07:16 CST 2021, time=2021-06-11, status=1, ipAttribution=)]

2021-11-08 xnjbao

请教大家：Independent Review阶段审稿人1和2分别提了3个和8个问题，编辑给了大修，审稿人3同意发表；回答了审稿人1和2的问题，提交修改稿后，开始显示的是Reviewer 1 and 2 are due to discuss in the interactive forum. 2天后，状态变为：We are awaiting a response from Reviewer 2 in the interactive forum.目前editor, reviewer 1 and 2状态都是active. 意思是审稿人1已经对修改稿做出了评价吗？状态还是active意味着审稿人1还是不支持发表？这个杂志的审稿过程与其他杂志相差太大了。有知道的战友，请告诉我哈，非常感谢！

58 10

展开10条回复

[GetPortalCommentsPageByObjectIdResponse(id=1247445, encodeId=b238124e445bc, content=偏重的研究方向：民族药理学;中药复方 经验分享：投稿第三天就收到上传原始数据的邮箱了。实验结果的原始数据好好，第一次遇到连把数据库下载的原始数据也要提供😄, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=224, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Tue Sep 06 12:10:42 CST 2022, time=2022-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224914, encodeId=fdc312249140c, content=有没有人知道，已经有了 handing editor 还仍然一直处于Editor Assigntment 阶段，一直不进入独立审稿是什么原因, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e3e6569517, createdName=ms4000001809359020, createdTime=Tue Jun 07 09:35:51 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211736, encodeId=d2e61211e3684, content=审稿速度:1.0 经验分享：问一下各位战友！independent Review阶段总共3位Reviewer，2位Reviewer给出了一些意见直接endorsed，1个Reviewer rejected，之后直接跳过了Interactive Review直接进入Review Finalized，互动论坛关闭，显示Review is ongoing，这个阶段我要重新提交修改过的手稿吗？还是先等待流程？求助各位战友！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07c65460274, createdName=ms1000000668586258, createdTime=Sat Apr 16 20:44:00 CST 2022, time=2022-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052871, encodeId=5d7f10528e123, content=偏重的研究方向：肿瘤 经验分享：The Associate Editor ✘✘is evaluating any revisions made to the manuscript to take a final decision。2个审稿人都endorsed了，这个一般要等多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=162, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35cb90736, createdName=kimbryant, createdTime=Sat Sep 18 19:22:37 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2181567, encodeId=3ab4218156e26, content=请问投稿后收到拒稿理由是：Ethical issues or Integrity concerns, or other breach of policy were identified in this manuscript that prevent further review or publication.是为什么呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=705f8475329, createdName=ms3000001867061317, createdTime=Sun Jan 14 16:14:08 CST 2024, time=2024-01-14, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1219504, encodeId=dfa8121950457, content=偏重的研究方向：中药 经验分享：投稿三周了还是Initial Validation正常嘛？？？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ff275558303, createdName=ms6000000643924855, createdTime=Sat May 14 02:51:05 CST 2022, time=2022-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068061, encodeId=3e2810680610e, content=请教大家：Independent Review阶段审稿人1和2分别提了3个和8个问题，编辑给了大修，审稿人3同意发表；回答了审稿人1和2的问题，提交修改稿后，开始显示的是Reviewer 1 and 2 are due to discuss in the interactive forum. 2天后，状态变为：We are awaiting a response from Reviewer 2 in the interactive forum.目前editor, reviewer 1 and 2状态都是active. 意思是审稿人1已经对修改稿做出了评价吗？状态还是active意味着审稿人1还是不支持发表？这个杂志的审稿过程与其他杂志相差太大了。有知道的战友，请告诉我哈，非常感谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=6aec55499, createdName=xnjbao, createdTime=Mon Nov 08 10:15:51 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208745, encodeId=97641208e45f2, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：药理学 经验分享：The Associate Editor is evaluating any revisions made to the manuscript to take a final decision. 在编辑这里停留了两周了，请问这是什么情况？ 之前两个审稿人，一个直接给了endorsed，一个revision后给了endorsed；现在编辑再做final decision 请问各位大神有相似的经验吗？ 23 Mar 2022 Review of Review Editor 2 finalized. 17 Mar 2022 Corresponding Author posted new comments. 26 Feb 2022 Interactive review forum activated automatically. 03 Feb 2022 Review of Reviewer 1 is finalized. 17 Jan 2022 Corresponding Autho submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=470d5595758, createdName=ms6000001226186802, createdTime=Tue Apr 05 12:00:40 CST 2022, time=2022-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051477, encodeId=e4b210514e733, content=请问官网publish之后，什么时候能在wos上检索得到呢？现在只有官网上才能查到, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210915/71f2be7dffda4b2fa4182e3c51618e51/c3ba98af130a45c79094f8381f667b4e.jpg, createdBy=bcc15439550, createdName=夏小正plus, createdTime=Wed Sep 15 13:17:45 CST 2021, time=2021-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972762, encodeId=c5129e2762bd, content=请问一下 substantial revision 接收概率大么？是小修的意思吗谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epS9bXfsQ9F45LRdNKKXSR3SceNj6EksI6D68yHJw3icDBH7OdtHgMsJZibhtxdrxsicRhanL2RGJv3Q/132, createdBy=968c2354707, createdName=陈述, createdTime=Fri Jun 11 09:07:16 CST 2021, time=2021-06-11, status=1, ipAttribution=)]

2022-04-05 ms6000001226186802

审稿速度:3.0 | 投稿命中率:75.0
偏重的研究方向：药理学
经验分享：The Associate Editor is evaluating any revisions made to the manuscript to take a final decision.
在编辑这里停留了两周了，请问这是什么情况？
之前两个审稿人，一个直接给了endorsed，一个revision后给了endorsed；现在编辑再做final decision
请问各位大神有相似的经验吗？

23 Mar 2022
Review of Review Editor 2 finalized.
17 Mar 2022
Corresponding Author posted new comments.
26 Feb 2022
Interactive review forum activated automatically.
03 Feb 2022
Review of Reviewer 1 is finalized.
17 Jan 2022
Corresponding Autho submitted manuscript.

79 10

展开10条回复

[GetPortalCommentsPageByObjectIdResponse(id=1247445, encodeId=b238124e445bc, content=偏重的研究方向：民族药理学;中药复方 经验分享：投稿第三天就收到上传原始数据的邮箱了。实验结果的原始数据好好，第一次遇到连把数据库下载的原始数据也要提供😄, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=224, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Tue Sep 06 12:10:42 CST 2022, time=2022-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224914, encodeId=fdc312249140c, content=有没有人知道，已经有了 handing editor 还仍然一直处于Editor Assigntment 阶段，一直不进入独立审稿是什么原因, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e3e6569517, createdName=ms4000001809359020, createdTime=Tue Jun 07 09:35:51 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211736, encodeId=d2e61211e3684, content=审稿速度:1.0 经验分享：问一下各位战友！independent Review阶段总共3位Reviewer，2位Reviewer给出了一些意见直接endorsed，1个Reviewer rejected，之后直接跳过了Interactive Review直接进入Review Finalized，互动论坛关闭，显示Review is ongoing，这个阶段我要重新提交修改过的手稿吗？还是先等待流程？求助各位战友！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07c65460274, createdName=ms1000000668586258, createdTime=Sat Apr 16 20:44:00 CST 2022, time=2022-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052871, encodeId=5d7f10528e123, content=偏重的研究方向：肿瘤 经验分享：The Associate Editor ✘✘is evaluating any revisions made to the manuscript to take a final decision。2个审稿人都endorsed了，这个一般要等多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=162, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35cb90736, createdName=kimbryant, createdTime=Sat Sep 18 19:22:37 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2181567, encodeId=3ab4218156e26, content=请问投稿后收到拒稿理由是：Ethical issues or Integrity concerns, or other breach of policy were identified in this manuscript that prevent further review or publication.是为什么呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=705f8475329, createdName=ms3000001867061317, createdTime=Sun Jan 14 16:14:08 CST 2024, time=2024-01-14, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1219504, encodeId=dfa8121950457, content=偏重的研究方向：中药 经验分享：投稿三周了还是Initial Validation正常嘛？？？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ff275558303, createdName=ms6000000643924855, createdTime=Sat May 14 02:51:05 CST 2022, time=2022-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068061, encodeId=3e2810680610e, content=请教大家：Independent Review阶段审稿人1和2分别提了3个和8个问题，编辑给了大修，审稿人3同意发表；回答了审稿人1和2的问题，提交修改稿后，开始显示的是Reviewer 1 and 2 are due to discuss in the interactive forum. 2天后，状态变为：We are awaiting a response from Reviewer 2 in the interactive forum.目前editor, reviewer 1 and 2状态都是active. 意思是审稿人1已经对修改稿做出了评价吗？状态还是active意味着审稿人1还是不支持发表？这个杂志的审稿过程与其他杂志相差太大了。有知道的战友，请告诉我哈，非常感谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=6aec55499, createdName=xnjbao, createdTime=Mon Nov 08 10:15:51 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208745, encodeId=97641208e45f2, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：药理学 经验分享：The Associate Editor is evaluating any revisions made to the manuscript to take a final decision. 在编辑这里停留了两周了，请问这是什么情况？ 之前两个审稿人，一个直接给了endorsed，一个revision后给了endorsed；现在编辑再做final decision 请问各位大神有相似的经验吗？ 23 Mar 2022 Review of Review Editor 2 finalized. 17 Mar 2022 Corresponding Author posted new comments. 26 Feb 2022 Interactive review forum activated automatically. 03 Feb 2022 Review of Reviewer 1 is finalized. 17 Jan 2022 Corresponding Autho submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=470d5595758, createdName=ms6000001226186802, createdTime=Tue Apr 05 12:00:40 CST 2022, time=2022-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051477, encodeId=e4b210514e733, content=请问官网publish之后，什么时候能在wos上检索得到呢？现在只有官网上才能查到, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210915/71f2be7dffda4b2fa4182e3c51618e51/c3ba98af130a45c79094f8381f667b4e.jpg, createdBy=bcc15439550, createdName=夏小正plus, createdTime=Wed Sep 15 13:17:45 CST 2021, time=2021-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972762, encodeId=c5129e2762bd, content=请问一下 substantial revision 接收概率大么？是小修的意思吗谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epS9bXfsQ9F45LRdNKKXSR3SceNj6EksI6D68yHJw3icDBH7OdtHgMsJZibhtxdrxsicRhanL2RGJv3Q/132, createdBy=968c2354707, createdName=陈述, createdTime=Fri Jun 11 09:07:16 CST 2021, time=2021-06-11, status=1, ipAttribution=)]

2021-09-15 夏小正plus

请问官网publish之后，什么时候能在wos上检索得到呢？现在只有官网上才能查到

63 10

展开10条回复

[GetPortalCommentsPageByObjectIdResponse(id=1247445, encodeId=b238124e445bc, content=偏重的研究方向：民族药理学;中药复方 经验分享：投稿第三天就收到上传原始数据的邮箱了。实验结果的原始数据好好，第一次遇到连把数据库下载的原始数据也要提供😄, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=224, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07dc5590988, createdName=ms4000001680289394, createdTime=Tue Sep 06 12:10:42 CST 2022, time=2022-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224914, encodeId=fdc312249140c, content=有没有人知道，已经有了 handing editor 还仍然一直处于Editor Assigntment 阶段，一直不进入独立审稿是什么原因, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=69, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e3e6569517, createdName=ms4000001809359020, createdTime=Tue Jun 07 09:35:51 CST 2022, time=2022-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211736, encodeId=d2e61211e3684, content=审稿速度:1.0 经验分享：问一下各位战友！independent Review阶段总共3位Reviewer，2位Reviewer给出了一些意见直接endorsed，1个Reviewer rejected，之后直接跳过了Interactive Review直接进入Review Finalized，互动论坛关闭，显示Review is ongoing，这个阶段我要重新提交修改过的手稿吗？还是先等待流程？求助各位战友！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07c65460274, createdName=ms1000000668586258, createdTime=Sat Apr 16 20:44:00 CST 2022, time=2022-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052871, encodeId=5d7f10528e123, content=偏重的研究方向：肿瘤 经验分享：The Associate Editor ✘✘is evaluating any revisions made to the manuscript to take a final decision。2个审稿人都endorsed了，这个一般要等多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=162, replyNumber=11, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=35cb90736, createdName=kimbryant, createdTime=Sat Sep 18 19:22:37 CST 2021, time=2021-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2181567, encodeId=3ab4218156e26, content=请问投稿后收到拒稿理由是：Ethical issues or Integrity concerns, or other breach of policy were identified in this manuscript that prevent further review or publication.是为什么呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=76, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=705f8475329, createdName=ms3000001867061317, createdTime=Sun Jan 14 16:14:08 CST 2024, time=2024-01-14, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1219504, encodeId=dfa8121950457, content=偏重的研究方向：中药 经验分享：投稿三周了还是Initial Validation正常嘛？？？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=48, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ff275558303, createdName=ms6000000643924855, createdTime=Sat May 14 02:51:05 CST 2022, time=2022-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068061, encodeId=3e2810680610e, content=请教大家：Independent Review阶段审稿人1和2分别提了3个和8个问题，编辑给了大修，审稿人3同意发表；回答了审稿人1和2的问题，提交修改稿后，开始显示的是Reviewer 1 and 2 are due to discuss in the interactive forum. 2天后，状态变为：We are awaiting a response from Reviewer 2 in the interactive forum.目前editor, reviewer 1 and 2状态都是active. 意思是审稿人1已经对修改稿做出了评价吗？状态还是active意味着审稿人1还是不支持发表？这个杂志的审稿过程与其他杂志相差太大了。有知道的战友，请告诉我哈，非常感谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=6aec55499, createdName=xnjbao, createdTime=Mon Nov 08 10:15:51 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208745, encodeId=97641208e45f2, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：药理学 经验分享：The Associate Editor is evaluating any revisions made to the manuscript to take a final decision. 在编辑这里停留了两周了，请问这是什么情况？ 之前两个审稿人，一个直接给了endorsed，一个revision后给了endorsed；现在编辑再做final decision 请问各位大神有相似的经验吗？ 23 Mar 2022 Review of Review Editor 2 finalized. 17 Mar 2022 Corresponding Author posted new comments. 26 Feb 2022 Interactive review forum activated automatically. 03 Feb 2022 Review of Reviewer 1 is finalized. 17 Jan 2022 Corresponding Autho submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=470d5595758, createdName=ms6000001226186802, createdTime=Tue Apr 05 12:00:40 CST 2022, time=2022-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1051477, encodeId=e4b210514e733, content=请问官网publish之后，什么时候能在wos上检索得到呢？现在只有官网上才能查到, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210915/71f2be7dffda4b2fa4182e3c51618e51/c3ba98af130a45c79094f8381f667b4e.jpg, createdBy=bcc15439550, createdName=夏小正plus, createdTime=Wed Sep 15 13:17:45 CST 2021, time=2021-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972762, encodeId=c5129e2762bd, content=请问一下 substantial revision 接收概率大么？是小修的意思吗谢谢！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=61, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83epS9bXfsQ9F45LRdNKKXSR3SceNj6EksI6D68yHJw3icDBH7OdtHgMsJZibhtxdrxsicRhanL2RGJv3Q/132, createdBy=968c2354707, createdName=陈述, createdTime=Fri Jun 11 09:07:16 CST 2021, time=2021-06-11, status=1, ipAttribution=)]

2021-06-11 陈述

请问一下 substantial revision 接收概率大么？是小修的意思吗谢谢！

61 10

展开10条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务